ClearPoint Neuro (CLPT) Asset Writedowns and Impairment (2013 - 2026)
ClearPoint Neuro (CLPT) reported Asset Writedowns and Impairment of -$95000.0 for Q1 2026, down 143.78% on a YoY basis from $217000.0 in Q1 2025, and up 51.53% sequentially from -$196000.0 in Q4 2025.
ClearPoint Neuro (CLPT) Asset Writedowns and Impairment (2013 - 2026) Analysis & Trends
ClearPoint Neuro (CLPT) has 8 years of Asset Writedowns and Impairment data on file, last reported at -$95000.0 in Q1 2026.
- For the quarter ending Q1 2026, Asset Writedowns and Impairment fell 143.78% year-over-year to -$95000.0; the trailing twelve-month figure through Mar 2026 stood at -$291000.0 (down 534.33% YoY), and the FY2025 full-year result was $21000.0, up 107.09% from the prior year.
- Asset Writedowns and Impairment grew to -$95000.0 in Q1 2026, from -$196000.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $449000.0 in Q3 2023 to a low of -$361000.0 in Q2 2024.
- A 5-year average of $55071.4 and a median of $13000.0 in 2022 frame the typical range for Asset Writedowns and Impairment.
- Across the five-year window, Asset Writedowns and Impairment slumped 2133.33% in 2022 and surged 1520.0% in 2023, its largest moves.
- Tracing CLPT's Asset Writedowns and Impairment over 5 years: stood at -$25000.0 in 2022, then surged by 1520.0% to $355000.0 in 2023, then sank by 40.56% to $211000.0 in 2024, then sank by 192.89% to -$196000.0 in 2025, then soared by 51.53% to -$95000.0 in 2026.
- Business Quant data shows CLPT's Asset Writedowns and Impairment at -$95000.0 in Q1 2026, -$196000.0 in Q4 2025, and $217000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | ClearPoint Neuro | 434.51 Mn | 398.91 Mn | 7.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -95,000.00 |
| Mar 31, 2026 | -95,000.00 |
| Dec 31, 2025 | -196,000.00 |
| Dec 31, 2025 | -196,000.00 |
| Mar 31, 2025 | 217,000.00 |
| Mar 31, 2025 | 217,000.00 |
| Dec 31, 2024 | 211,000.00 |
| Dec 31, 2024 | 211,000.00 |
| Jun 30, 2024 | -361,000.00 |
| Jun 30, 2024 | -361,000.00 |
| Mar 31, 2024 | -146,000.00 |
| Mar 31, 2024 | -146,000.00 |
| Dec 31, 2023 | 355,000.00 |
| Dec 31, 2023 | 355,000.00 |
| Sep 30, 2023 | 449,000.00 |
| Sep 30, 2023 | 449,000.00 |
| Jun 30, 2023 | 283,000.00 |
| Jun 30, 2023 | 283,000.00 |
| Mar 31, 2023 | 171,000.00 |
| Mar 31, 2023 | 171,000.00 |